A5004025365- Multiple Sclerosis Research Studies
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Renal Transplantation Outcomes and Treatments
- Peripheral Neuropathies and Disorders
- Obstructive Sleep Apnea Research
- Schizophrenia research and treatment
- Polyomavirus and related diseases
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Organ Transplantation Techniques and Outcomes
- Neuroscience of respiration and sleep
- Sleep and Wakefulness Research
- Acute Ischemic Stroke Management
- Sleep and related disorders
- Neurological Complications and Syndromes
- Biosimilars and Bioanalytical Methods
- Mental Health Treatment and Access
- Neurosurgical Procedures and Complications
- Immunodeficiency and Autoimmune Disorders
- Systemic Sclerosis and Related Diseases
- Cerebral Venous Sinus Thrombosis
- Health Systems, Economic Evaluations, Quality of Life
Roche (Switzerland)
2016-2025
University of Bern
2016-2025
Hôpital Pellegrin
2025
Hôpital Paul-Brousse
2025
University Hospital of Bern
2016-2025
Médecins du Monde
2025
Hamilton Medical (Switzerland)
2024
Oxford University Press (United Kingdom)
2018
Alfried Krupp Hospital
2017
Zimmer Biomet (Switzerland)
2016
Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent relapse activity (PIRA), with PIRA regarded a feature primary and secondary progressive sclerosis.To investigate the contributions vs relapse-independent to overall confirmed accumulation (CDA) assess respective baseline prognostic factors outcomes 2 treatments.Analyses occurred from July 2015 February 2020 on pooled data intention-to-treat population identical,...
Renal transplantation faces challenges: the organ shortage resulting in extended waiting times and an aging population death with a functioning graft. The Eurotransplant Senior Program (ESP) allocates kidneys within narrow geographic area from donors aged >/=65 years to recipients regardless of HLA. This analysis investigates impact ESP on time, graft patient survival. group (n = 1406, old old) was compared two groups allocated via Kidney Allocation System (ETKAS) either similar donor age...
<h3>Objective</h3> In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare the efficacy of adding tocilizumab that switching monotherapy. <h3>Methods</h3> Double-blind, 2-year study in which adults RA (DAS28 >4.4) methotrexate were randomly assigned either continue addition (MTX+TCZ) 8 mg/kg every 4 weeks or switch and placebo (TCZ+PBO). The primary endpoint was DAS28–erythrocyte sedimentation rate (ESR) remission at week 24. Secondary objectives included other...
Background: Chronic lesion activity driven by smoldering inflammation is a pathological hallmark of progressive forms multiple sclerosis (MS). Objective: To develop method for automatic detection slowly expanding/evolving lesions (SELs) on conventional brain magnetic resonance imaging (MRI) and characterize such SELs in primary MS (PPMS) relapsing (RMS) populations. Methods: We defined as contiguous regions existing T2 showing local expansion assessed the Jacobian determinant deformation...
Chronic active and slowly expanding lesions with smouldering inflammation are neuropathological correlates of progressive multiple sclerosis pathology. T1 hypointense volume signal intensity on T1-weighted MRI reflect brain tissue damage that may develop within newly formed acute focal inflammatory or in chronic pre-existing without signs inflammation. Using a recently developed method to identify expanding/evolving vivo from longitudinal conventional T2- scans, we measured the relative...
BackgroundNeurofilament light chain (NfL), a neuronal cytoskeletal protein that is released upon neuroaxonal injury, associated with multiple sclerosis (MS) relapsing activity and has demonstrated some prognostic ability for future relapse-related disease progression, yet its value in assessing non-relapsing progression remains unclear.MethodsWe examined baseline longitudinal blood NfL levels 1421 persons MS (RMS) 596 primary progressive (PPMS) from the pivotal ocrelizumab trials....
<h3>Objective</h3> To assess the 1-year efficacy and safety of a regimen tocilizumab plus methotrexate or placebo, which was augmented by treat-to-target strategy from week 24. <h3>Methods</h3> ACT-RAY double-blind, 3-year trial. Adults with active rheumatoid arthritis despite were randomised to add ongoing (add-on strategy) switch placebo (switch strategy). Tocilizumab 8 mg/kg administered every 4 weeks. Conventional open-label disease-modifying antirheumatic drugs (DMARDs) other than added...
Background and Purpose— Five randomized controlled trials have consistently shown that mechanical thrombectomy (MT) in addition to best medical treatment (±intravenous tissue-type plasminogen activator) improves outcome after acute ischemic stroke patients with large artery anterior circulation stroke. Whether direct MT is equally effective as combined intravenous thrombolysis (ie, bridging thrombolysis) remains unclear. Methods— We retrospectively compared clinical radiological outcomes 167...
Background Current clinical assessments of people with multiple sclerosis are episodic and may miss critical features functional fluctuations between visits. Objective The goal the research was to assess feasibility remote active testing passive monitoring using smartphones smartwatch technology in respect adherence satisfaction FLOODLIGHT test battery. Methods People (aged 20 57 years; Expanded Disability Status Scale 0-5.5; n=76) healthy controls (n=25) performed battery, comprising tests...
Objective To assess the efficacy and safety of tocilizumab (TCZ) plus methotrexate/placebo (MTX/PBO) over 2 years course disease activity in patients who discontinued TCZ due to sustained remission. Methods ACT-RAY was a double-blind 3-year trial. Patients with active rheumatoid arthritis despite MTX were randomised add ongoing (add-on strategy) or switch PBO (switch strategy). Using treat-to-target approach, open-label conventional synthetic disease-modifying antirheumatic drugs (csDMARDs),...
Background: Sensor-based monitoring tools fill a critical gap in multiple sclerosis (MS) research and clinical care. Objective: The aim of this study is to assess performance characteristics the Floodlight Proof-of-Concept (PoC) app. Methods: In 24-week (clinicaltrials.gov: NCT02952911), smartphone-based active tests passive assessed cognition (electronic Symbol Digit Modalities Test), upper extremity function (Pinching Test, Draw Shape gait balance (Static Balance U-Turn Walk Passive...
Abstract Floodlight Open was a global, open-access, digital-only study designed to understand the drivers and barriers in deployment use of smartphone app naturalistic setting broad population people with without multiple sclerosis (MS). The utilised app: ‘bring-your-own-device’ solution that remotely measures user’s mood, cognition, hand motor function, gait postural stability via sensor-based tests requiring active user input (‘active tests’). Levels mobility participants (‘life-space...
Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS). Post hoc exploratory analyses were performed in a treatment-naive patients RMS who received ≥1 dose OCR multicenter OPERA I/II (NCT01247324/NCT01412333) studies....
Background. Reducing side effects of immunosuppressive regimens has become a priority in transplantation medicine because the large number patients and grafts that succumb to infection short term cardiovascular disease long term. The Symphony study was 12-month prospective, randomized, open-label, multi-centre, four parallel arm aimed evaluate safety efficacy low-dose compared with standard-dose regimen renal transplant recipients. This sub-analysis focuses on specific toxicities observed...
<h3>Objective</h3> To evaluate the safety and efficacy of tocilizumab in clinical practice patients with rheumatoid arthritis (RA) inadequate responses (IR) to disease-modifying antirheumatic drugs (DMARDs) or both DMARDs tumour necrosis factor α inhibitors (TNFis). <h3>Methods</h3> Patients—categorised as TNFi-naive, TNFi-previous (washout) TNFi-recent (no washout) —received open-label (8 mg/kg) every 4 weeks ± for 24 weeks. Adverse events (AEs) treatment discontinuations were monitored....
Abstract Introduction Our objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients rheumatoid arthritis (RA). Methods Data receiving tocilizumab or placebo MEASURE study were analysed. We investigated associations at baseline during treatment among parameters haemoglobin homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6...
Background and objectives Definition of individual risk profile is the first step to implement strategies keep delicate balance between under- overimmunosuppression after kidney transplantation. Design, setting, participants, & measurements We used data from Efficacy Limiting Toxicity Elimination Symphony Study (1190 patients 2002 2004) model rejection infection in year External validation was performed a study population Fixed-Dose Concentration-Controlled Trial (630 2003 2006). Results...
Randomized controlled trials have shown that mechanical thrombectomy (MT) plus best medical treatment improves outcome in stroke patients with large-vessel occlusion the anterior circulation. Whether direct MT is equally effective as bridging thrombolysis (intravenous MT) intravenous eligible remains unclear.We compared clinical and radiological outcomes at 3 months 249 111 receiving for circulation from 2 prospective registries (study period Essen: June 2012 to August 2013, Bern February...
Intravenous thrombolysis and endovascular therapy (IVT/EVT) are evidence-based treatments for adults with arterial ischemic stroke (AIS). However, randomized controlled trials in pediatric patients lacking. This study aimed to describe feasibility, safety, outcome of IVT/EVT children AIS.This retrospective (01/2000-12/2015) included a multicenter, population-based consecutive cohort aged 1 month 16 years, diagnosed AIS presenting National Institutes Health Stroke Scale (pedNIHSS) ≥ 4....